HFA Premium Access

The senolyitc drug ABT-263 reverses HFpEF-associated inflammation, endothelial inflammation and fibrosis

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Congress Session

About the speaker

Miss Elsa Silva

I3s (Institute for Research and Innovation in Health), Porto (Portugal)
0 follower

9 more presentations in this session

Blood pressure response and safety outcomes with vericiguat in the VICTORIA trial

Speaker: Doctor C. Lam (Singapore, SG)


Long-term outcomes in heart failure with preserved ejection fraction: predictors of cardiovascular and non-cardiovascular mortality

Speaker: Ms A. Shahim (Stockholm, SE)


The impact of multimorbidity on mortality in heart failure with reduced ejection fraction (HFrEF): Which comorbidities matter most?

Speaker: Doctor P. Dewan (Glasgow, GB)


Acute changes in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF

Speaker: Doctor K. Docherty (Glasgow, GB)


Clinical outcome predictions for the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial

Speaker: Doctor R. Mentz (Durham, US)


Access the full session

Chronic Heart Failure - Pathophysiology and Mechanisms 2

Speakers: Miss E. Silva, Doctor C. Lam, Ms A. Shahim, Doctor P. Dewan, Doctor K. Docherty...

About the event


Heart Failure 2021 Online Congress

29 June - 1 July 2021

Sessions Presentations

Related content

ESC Premium Access

Sudden cardiac death in the young: utility of postmortem genetic testing and how to screen.

29 August 2021

ESC Premium Access

A multidisciplinary approach to diagnosing and managing heart failure with preserved ejection fraction

27 August 2021

ESC Premium Access

Multimodality imaging in the diagnosis of left ventricular non-compaction cardiomyopathy.

27 August 2021

This platform is supported by

logo Novo Nordisk